Skip to main content
Log in

Medullary Thyroid Carcinoma in the IARC/WHO Neuroendocrine Schema

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Rindi G, Mete O, Uccella S, Basturk O, La RS, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 2022;33:115-54.

    Article  CAS  Google Scholar 

  2. Alzumaili B, Xu B, Spanheimer PM, Tuttle RM, Sherman E, Katabi N, et al. Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Mod Pathol 2020;33:1690-701.

    Article  CAS  Google Scholar 

  3. Fuchs TL, Nassour AJ, Glover A, Sywak MS, Sidhu SB, Delbridge LW, et al. A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. Am J Surg Pathol 2020;44:1419-28.

    Article  Google Scholar 

  4. Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA, et al. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. J Clin Oncol 2022;40:96-104.

    Article  Google Scholar 

  5. Vissio E, Maletta F, Fissore J, Osella AS, Retta F, Brizzi MP, et al. External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort. Endocr Pathol 2022 in press.

  6. Williams JF, Zhao M, Najdawi F, Ahmadi S, Hornick JL, Wong KS, et al. Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study. Endocr Pathol 2022 in press.

  7. Erovic BM, Kim D, Cassol C, Goldstein DP, Irish JC, Asa SL, et al. Prognostic and predictive markers in medullary thyroid carcinoma. Endocr Pathol 2012;23:232-42.

    Article  CAS  Google Scholar 

  8. Le M-K, Kawai M, Odate T, Vuong HG, Oishi N, Kondo T. Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database. Endocr Pathol 2022. in press.

  9. Khandakar H, Agarwal S, Sharma MC, Kandasamy D, Bal C, Rathode Y, et al. Amphicrine Medullary Thyroid Carcinoma - a Case-Based Review Expanding on Its MUC Expression Profile. Endocr Pathol 2022 in press.

Download references

Acknowledgements

Dr. Ozgur Mete is the Editor-in-Chief of Endocrine Pathology. The peer review of this article was handled by an independent senior editor.

Author information

Authors and Affiliations

Authors

Contributions

SLA and OM wrote the manuscript.

Corresponding authors

Correspondence to Sylvia L. Asa or Ozgur Mete.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asa, S.L., Mete, O. Medullary Thyroid Carcinoma in the IARC/WHO Neuroendocrine Schema. Endocr Pathol 33, 346–347 (2022). https://doi.org/10.1007/s12022-022-09728-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-022-09728-y

Navigation